Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

rcised prior to the effective time of the Merger will terminate. Any issued and outstanding stock options with an exercise price per share less than $3.00 will be converted into the right to receive a payment equal to the product of (1) the excess of $3.00 per share over the exercise price per share of such stock options and (2) the number of shares of SGX common stock subject to such stock options.

The completion of the Merger is subject to the satisfaction or waiver of a number of closing conditions, including, among others, (1) adoption of the Merger Agreement by the holders of a majority of SGX's outstanding common stock, (2) subject to certain exceptions, the absence of any material adverse effect on SGX from and after the date of the Merger Agreement, (3) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (4) the absence of any legal prohibitions on the closing of the Merger and (5) subject to certain exceptions, the continued accuracy of SGX's representations and warranties as of the effective time of the Merger.

The special meeting of stockholders to consider and vote upon the proposal to adopt the Merger Agreement and to transact such other business as may properly come before the special meeting (or any adjournment, postponement or continuance thereof) is scheduled for 9:00 a.m., California time, on August 20, 2008, at SGX's corporate headquarters located at 10505 Roselle Street, San Diego, California 92121.

Additional Information

SGX filed a definitive proxy statement with the Securities and Exchange Commission on July 21, 2008 with respect to the proposed merger transaction with Eli Lilly and Company. Before making any voting or investment decision with respect to the merger, investors and stockholders of SGX are urged to read the proxy statement and the other relevant materials carefully in their entirety because they contain important information ab
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:3/4/2015)... March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) ... completed a collaborative research program with Emerald ... Fast Collective Evolution Technology (FACET), Emerald Logic ... measurements obtained from each of 798 patients ... clinical trials ASSERT, SUSTAIN and ASSURE. The ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... to empathize with others is partially determined by genes, ... of Wisconsin-Madison and Oregon Health and Science University (OHSU). ... mice learned to associate a sound played in a ... mouse in that cage respond with squeaks of distress. ...
... & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) ... (FDA) has asked for additional information regarding the ... CONSTA(R) (risperidone) Long-Acting Injection. The sNDA, submitted in ... adjunctive maintenance treatment to delay the occurrence of ...
... Life Sciences Companies to Accelerate Time to Value ... Inc., the global leader empowering enterprises to realize ... formation of a partnership with Ceiba Solutions, Inc., ... business application integrations to help customers achieve a ...
Cached Biology Technology:Mouse study reveals genetic component of empathy 2Mouse study reveals genetic component of empathy 3FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 2FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 3FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 4FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 5SciQuest Announces Strategic Alliance with Ceiba Solutions 2SciQuest Announces Strategic Alliance with Ceiba Solutions 3SciQuest Announces Strategic Alliance with Ceiba Solutions 4
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... linked to too much growth in patients has now ... the gene can lead to very different conditions, according ... Genetics . IMAGe* syndrome is a rare developmental ... than average body and organ size. Without treatment, the ...
... PHILADELPHIA By pairing an intimate knowledge of immune-system ... cross-disciplinary team at the University of Pennsylvania has arrived ... strategy to track down parasites that is similar to ... tuna use to hunt their prey. ...
... Researchers reporting online on May 24 in the Cell ... evidence that areas closed to all fishing are helping ... scientists applied a forensic DNA profiling approach to track ... of marine reserves on Australia,s Great Barrier Reef. , ...
Cached Biology News:Variations of a single gene can lead to too much or too little growth, study shows 2T cells 'hunt' parasites like animal predators seek prey, a Penn Vet-Penn Physics study reveals 2T cells 'hunt' parasites like animal predators seek prey, a Penn Vet-Penn Physics study reveals 3T cells 'hunt' parasites like animal predators seek prey, a Penn Vet-Penn Physics study reveals 4DNA evidence shows that marine reserves help to sustain fisheries 2
Immulon 1 B 1x12 Strip, flat bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
...
Small bottle for hybridization 150 x 35mm...
Biology Products: